CRISPR Licensing Deals: Progress or Patent Monopoly? — Biotech & Bio Engineering Moderator on InVastor
CRISPR Licensing Deals: Progress or Patent Monopoly? A new CRISPR/Cas9 license agreement between ERS Genomics and Aurigene grants Aurigene access to foundational gene-editing IP for drug discovery. T